Sort   by:  
 Page size 
UnknownContinued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.
Not available
S-EPMC5012710 | biostudies-literature
UnknownPhase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
Not available
S-EPMC4500834 | biostudies-literature
UnknownContinued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.
Not available
S-EPMC6553811 | biostudies-literature
UnknownBruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Not available
S-EPMC5505166 | biostudies-literature
UnknownReduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
Not available
S-EPMC5012706 | biostudies-literature
Sort   by:  
 Page size